Attempt #68

Job: 54 • Audience: medical_affairs • Passed: True • Created: 2026-02-17 19:20:56.593778

Routing Reasons

ML fallback: low confidence (40% < 57%); The document is a Consumer Medicine Information (CMI) leaflet for the drug Abacavir/Lamivudine Viatris, providing detailed medical information about the drug's usage, side effects, contraindications, and precautions.; The content is intended to ensure safe and effective use of the medicine, emphasizing medical advice, monitoring, interaction with other drugs, and hypersensitivity reactions.; The language and content are highly clinical and medically oriented, aimed at communicating medical details to healthcare professionals or medical affairs teams to support their role in patient education and pharmacovigilance.

One-line Summary

Abacavir/Lamivudine Viatris is a combination antiretroviral therapy used with other agents to slow HIV progression, requiring careful monitoring for hypersensitivity and interactions.

Decision Bullets

• Scientific Summary: Abacavir/Lamivudine Viatris slows HIV replication but does not cure infection, lowering viral load and delaying AIDS onset with daily administration alongside other antiretrovirals.
• Evidence Gaps: Limited detailed data on long-term safety in pregnancy and breastfeeding; need for more robust pharmacogenetic screening implementation evidence.
• Medical Insights: Hypersensitivity reactions require immediate cessation; genetic testing for HLA-B*5701 can mitigate fatal risks; drug-drug interactions necessitate dosing adjustments and vigilance.
• Stakeholder Considerations: Prescribers must educate patients on adherence, side effect monitoring, and transmission risk; pharmacists ensure interaction checks; patients require support for adherence and awareness.
• Next Steps: Enhance genetic screening uptake, reinforce patient education on hypersensitivity, monitor for emerging interactions, and address safety data gaps in special populations.

Tags

• HIV
• antiretroviral therapy
• abacavir
• lamivudine
• hypersensitivity
• drug interactions
• patient safety

Key Clues

• Combination of abacavir and lamivudine for HIV treatment
• Used with other antiretrovirals to slow HIV progression
• Serious hypersensitivity reaction linked to HLA-B*5701 gene
• Requires regular blood tests to monitor side effects
• Potential interactions with methadone and trimethoprim-sulphamethoxazole
• Not a cure; continued transmission risk
• Avoid re-exposure after hypersensitivity

Mind Map (Raw)

mindmap
  root((Abacavir/Lamivudine Viatris))
    Uses
      HIV Treatment
      Combined Antiretroviral Therapy
    Mechanism
      Inhibits HIV Replication
      Delays AIDS Progression
    Safety
      Hypersensitivity Reaction
        HLA-B*5701 Association
        Life-Threatening Risk
      Side Effects
        Nausea
        Rash
        Headache
    Monitoring
      Regular Blood Tests
      Symptom Vigilance
    Drug Interactions
      Methadone Dose Adjustment
      Avoid Emtricitabine
      Co-Trimoxazole Concern
    Patient Counseling
      Adherence Importance
      Transmission Risk
      Alert Card Usage
    Evidence Gaps
      Pregnancy/Breastfeeding Data
      Genetic Screening Implementation
    Next Steps
      Improve Screening
      Education
      Safety Surveillance

Evaluator Verdict

{
  "fail_reasons": [],
  "fix_instructions": [],
  "missing_sections": [],
  "pass": true,
  "support_warning": true,
  "word_count": 174
}

Raw JSON

These are the JSON payloads stored per attempt.

{
  "decision_bullets": [
    "Scientific Summary: Abacavir/Lamivudine Viatris slows HIV replication but does not cure infection, lowering viral load and delaying AIDS onset with daily administration alongside other antiretrovirals.",
    "Evidence Gaps: Limited detailed data on long-term safety in pregnancy and breastfeeding; need for more robust pharmacogenetic screening implementation evidence.",
    "Medical Insights: Hypersensitivity reactions require immediate cessation; genetic testing for HLA-B*5701 can mitigate fatal risks; drug-drug interactions necessitate dosing adjustments and vigilance.",
    "Stakeholder Considerations: Prescribers must educate patients on adherence, side effect monitoring, and transmission risk; pharmacists ensure interaction checks; patients require support for adherence and awareness.",
    "Next Steps: Enhance genetic screening uptake, reinforce patient education on hypersensitivity, monitor for emerging interactions, and address safety data gaps in special populations."
  ],
  "evaluator": {
    "fail_reasons": [],
    "fix_instructions": [],
    "missing_sections": [],
    "pass": true,
    "support_warning": true,
    "word_count": 174
  },
  "key_clues": [
    "Combination of abacavir and lamivudine for HIV treatment",
    "Used with other antiretrovirals to slow HIV progression",
    "Serious hypersensitivity reaction linked to HLA-B*5701 gene",
    "Requires regular blood tests to monitor side effects",
    "Potential interactions with methadone and trimethoprim-sulphamethoxazole",
    "Not a cure; continued transmission risk",
    "Avoid re-exposure after hypersensitivity"
  ],
  "tags": [
    "HIV",
    "antiretroviral therapy",
    "abacavir",
    "lamivudine",
    "hypersensitivity",
    "drug interactions",
    "patient safety"
  ]
}